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Abstract
Background Bariatric patients often suffer from vitamin
D deficiency (VDD), and both, morbid obesity and
VDD, are related to non-alcoholic fatty liver disease.
However, limited data are available regarding best
strategies for treating VDD, particularly, in bariatric pa-
tients undergoing omega-loop gastric bypass (OLGB).
Therefore, we examined the efficacy and safety of a
forced vitamin D dosing regimen and intervention ef-
fects in liver fibrotic patients.
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Clinicaltrials.gov (NCT02092376) at https://clinicaltrials.gov/
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Methods In this double-blind, randomized, placebo-
controlled trial, 50 vitamin D-deficient patients undergoing
OLGB were randomly assigned to receive, in the first month
postoperatively, oral vitamin D3 (≤3 doses of 100,000 IU;
intervention group) or placebo as loading dose (control group)
with subsequent maintenance dose (3420 IU/day) in both
groups until 6-month visit.
Results Compared with control group, higher increase of
25(OH)D (67.9 (21.1) vs. 55.7 nmol/L (21.1); p = 0.049) with
lower prevalence of secondary hyperparathyroidism (10 vs.
24 %; p = 0.045) was observed in intervention group. No
(serious) adverse events related to study medication were
found. The loading dose regimen was more effective in in-
creasing 25(OH)D in patients with significant liver fibrosis
while this was not the case for conventional supplementation
(placebo with maintenance dose) (71.5 (20.5) vs. 22.5 nmol/L
(13.8); p = 0.022; n = 14).
Conclusions Our findings indicate that a high vitamin D3
loading dose, in the first month postoperatively, with subse-
quent maintenance dose is effective and safe in achieving
higher vitamin D concentrations in OLGB patients.
Unexpectedly, it is more effective in patients with significant
liver fibrosis which is of potentially high clinical relevance
and requires further investigation.
Keywords Vitamin D . Vitamin D supplementation .
Obesity . Gastric bypass . Omega-loop gastric bypass .
Weight loss . Secondary hyperparathyroidism . Liver
fibrosis
Introduction
Vitamin D3 (cholecalciferol), derived both from dermal
synthesis and dietary sources (e.g., oily fish and supple-
ments), is first modified mainly in the liver by 25-
hydroxylation to generate the main circulating form, 25-
hydroxy vitamin D (25(OH)D). This is followed by 1α-
hydroxylation to produce the active hormone, 1,25-dihy-
droxy vitamin D (1,25(OH)2D) mainly in the kidney and
also at numerous extra-renal sites [1]. The vitamin D re-
ceptor (VDR) is expressed almost ubiquitously and regu-
lates, upon ligand binding, the expression of over 200
genes [2]. In addition, non-VDR-mediated vitamin D ac-
tions have been identified in various tissues and this field
of research is rapidly expanding [3]. It is therefore not
surprising that the vitamin D endocrine system impacts
the function of virtually every organ system in the human
body. Vitamin D deficiency has been connected by mech-
anistic, epidemiologic, and clinical intervention studies
with the pathogenesis of numerous diseases [3]. Obese
patients are at higher risk of vitamin D deficiency com-
pared with non-obese individuals [4], which seems to be
best explained by the dilution of vitamin D and 25(OH)D
in the expanded adipose compartment [5, 6]. More sophis-
ticated pharmacokinetic studies are needed to clarify de-
tails such as the contribution of the adipose tissue itself to
the metabolism of vitamin D. Obesity is also associated
with non-alcoholic fatty liver disease (NAFLD), which
comprises a disease spectrum ranging from simple
steatosis to steatohepatitis, fibrosis, cirrhosis, and finally
hepatocellular carcinoma and is the most prevalent chron-
ic liver disease in industrialized countries [7]. Vitamin D
insufficiency (25(OH)D <75 nmol/L) is associated with
NAFLD independently from diabetes, insulin resistance,
and metabolic syndrome [8]. Increased stages of liver fi-
brosis are associated with lower vitamin D concentrations
in morbidly obese patients [9], suggesting a causal role of
vitamin D deficiency in the pathogenesis of liver fibrosis.
Vitamin D has even been proposed as a therapeutic agent
for this condition [10].
Bariatric surgery is an effective method to treat obesity,
(pre)diabetes [11, 12], and NAFLD [13] in morbidly obese
patients and is associated with long-term weight loss and de-
creased overall mortality [14]. Due to gastric restriction and
malabsorption following the gastric bypass procedure, 50–
96 % of bariatric patients suffer from vitamin D deficiency,
in addition to the obesity-related nutritional deficiencies
[15–18].
Only limited data are available regarding the best strategies
for treating vitamin D deficiency in bariatric patients. The
clinical practice guidelines differ among scientific societies
and often lack scientifically founded criteria. Therefore, there
is need for high quality randomized controlled trials to provide
reliable evidence for the recommendations on vitamin D sup-
plementation in bariatric patients [19].
The primary aim of this study was to examine the efficacy
and safety of a forced vitamin D dosing regimen (up to three
oral loading doses in the first month postoperatively, interven-
tion group) vs. conventional supplementation (placebo with
following maintenance doses, control group) on parameters of
vitamin D metabolism in morbidly obese, vitamin D-deficient
patients undergoing omega-loop gastric bypass (OLGB)
6 months after surgery. In addition, given the high prevalence
of liver fibrosis in these patients and the intricate role of vita-
min D in this condition [9], we assessed markers of vitamin D
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metabolism in liver biopsies from the subgroup of patients
affected by significant liver fibrosis.
Subjects and Methods
The BLink Between Obesity and Vitamin D^ (LOAD) study
conducted from April 2014 to October 2015 in Vienna
(Austria), was a 6-month double-blind, placebo-controlled,
randomized clinical trial with a parallel-group design in bar-
iatric patients. The effects of up to three oral vitamin D3 load-
ing doses in the first month postoperatively followed by a
maintenance dose (intervention group) was compared with
placebo followed by a maintenance daily dose (control group)
on 25(OH)D concentration and other vitamin D metabolism
parameters. The details on design and the used materials and
methods of the study have been previously published [20].
Participant Recruitment and In- and Exclusion Criteria
Bariatric patients with following inclusion criteria were re-
cruited: men and women aged 18–100 years with planned
OLGB surgery, serum 25(OH)D concentrations of
<75 nmol/L, and body weight <140 kg (due to body weight
limitation of the dual energy X-ray absorptiometry (DEA)).
Specific exclusion criteria included any other planned form of
bariatric surgery than OLGB, hypo- and hypercalcemia, renal
insufficiency (creatinine >133 μmol/L or glomerular filtration
rate <50mLmin−1 1.73m−2), or primary hyperparathyroidism
[20]. In- and out-patients of the Obesity Clinics at the
Department of Internal Medicine III or the Department of
Surgery in the General Hospital of Vienna were recruited be-
tween April 2014 and April 2015. All study procedures were
reviewed and approved by the local Ethics Committee of the
Medical University of Vienna (No. 1899/2013) and by the
Austrian Competent Authority (No. LCM-718280-0001) and
comply with the Declaration of Helsinki [21]. Moreover, the
protocol was registered at clinicaltrials.gov (identifier:
NCT02092376) and EudraCT (identifier: 2013-003546-16).
All study participants provided signed informed consent.
The study methods are in accordance with the Consolidated
Standards of Reporting Trials (CONSORT) guidelines for
reporting randomized trials [22].
Sample size calculation was based on previously published
data from 50 bariatric patients who underwent OLGB [18]. On
basis of an assumed 20 % dropout rate (including loss to
follow-up), we estimated a total sample size of 50 patients
(25 in each group) by using 80 % statistical power and a
two-sided significance level of 0.05 to detect a 25(OH)D dif-
ference of 30 nmol/L (standard deviation, 35) between inter-
vention and control groups after 6 months.
Study Design and Randomization
After collecting baseline data, eligible patients were allocated
to receive either vitamin D3 (intervention group) or placebo
(control group) with a computer-generated randomization
scheme in a 1:1 ratio, stratified by 25(OH)D, age, and gender
level by a blinded study coordinator using the BRandomizer
for Clinical Trials 1.8.1^ [23]. Randomization was carried out
during the baseline assessment, after the patient had signed the
informed consent form. Everybody involved in the study was
blinded to the randomization status. Allocation was performed
by consecutively numbered dark bottles with either vitamin
D3 (cholecalciferol diluted in medium-chain triglycerides:
Oleovit D3 drops, Fresenius) or placebo (carrier oil of
medium-chain triglycerides) loading dose, labeled with the
randomization number, which were created and bottled by
the in-house hospital pharmacy, so as to blind both study
subjects and investigators.
Vitamin D Dosing Regimen
In the field of pharmacology, a loading dose is an amount of
drug designed to fill the central volume of distribution for a
drug to a concentration that matches the final plateau concen-
tration achieved with the maintenance dose. The purpose is to
achieve this final plateau sooner than the four half-lives re-
quired, if the drug is simply administered at the maintenance
dose rate [24]. For vitamin D3, the functional half-life within
the body is in the range of 2 to 3 months [25]. Accordingly, the
loading dose for the intervention group was calculated as the
cumulative maintenance dose that was planned to be given
through one functional half-life of vitamin D in the body
(loading dose = (daily maintenance dose) × (60–90 days)).
Moreover, it is safer not to take vitamin D at a dose beyond
100,000 IU at one time to allow vitamin D to clear from the
circulation between each increment of the loading dose [1]. In
that regard, the chosen loading dose of 300,000 IU vitamin D3
(cholecalciferol) was divided into three doses (each
100,000 IU) and given on day 1 or 2, 2 weeks, and 4 weeks
postoperatively with subsequent administration of the mainte-
nance dose until the 6-month visit in the intervention group
[20]. The first loading dose was given on day 1 or 2 after
surgery, followed by the second (2 weeks) and third adminis-
trations (4 weeks postoperatively) if 25(OH)D serum concen-
tration remained below 75 nmol/L. The maximum loading
dose for the intervention group was 300,000 IU. After the last
loading dose, a maintenance dose of 3420 IU/day (approxi-
mately translating to 24,000 IU/week) was given. The control
group received placebo as loading dose and subsequently the
maintenance dose, the same way as the intervention group. A
detailed illustration of the dosing regimen is depicted in the
study protocol [20]. At each study visit after surgery, partici-
pants received a monthly supply of study medication (Oleovit
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D3 drops, Fresenius, containing 12.5 mL of cholecalciferol in
medium-chain triglycerides carrier oil; 1 drop = 400 IU).
Every week, the patients received instructions and further re-
minders via text messages to take the supplement (mainte-
nance dose). The patients were instructed to return empty
bottles at the monthly study visit.
Assessment of Variables
At baseline (before randomization), age, sex, medical history
(e.g., comorbidities, prescribed medication) were collected
[20]. The following set of evaluations was obtained for each
participant before surgery and 0.5, 1, 2, 3, 4, 5, and 6 month(s)
postoperatively: height and body weight (measured with the
calibrated scale seca mBCA 515), waist circumference mea-
sured with an inelastic tape, supplement use, and parameters
of vitamin D metabolism (25(OH)D (nmol/L), 1,25(OH)2D
(pg/mL), intact parathyroid hormone PTHi (pg/mL), and
albumin-corrected calcium Ca (mmol/L)) [26]. Secondary hy-
perparathyroidism (SHPT) was defined as PTHi >65 pg/mL
with simultaneous normal values for creatinine, calcium, and
inorganic phosphate. Daily total energy (kcal), relative energy
from protein (%), carbohydrate (%), fat (%), vitamin D (μg),
and calcium (mg) intakes were calculated from 5-day food
records 1 week before surgery (baseline) and 1, 3, and
6 month(s) after surgery. The computation of nutrient intake
was carried out with the nutritional software nut.s science
(dato Denkwerkzeuge, v1.29.34, Austria). Additionally, habit-
ual sun exposure was assessed by a series of questions for
which categorical response options were provided [27] such
as Bhours spent outside between 9 a.m. and 3 p.m.^ during the
week (h/week), during the weekend (h/weekend), Bregular
going to the tanning salon^ (yes, no), and Busing sunscreen^
(yes, no). Furthermore, an average time spent outside was
calculated (h/week). Season was defined as spring (March–
May), summer (June–August), autumn (September–
Novembe r ) , and win t e r (December–Februa ry ) .
Supplementation adherence was reviewed by medication
counts.
Surgical Technique
All procedures were performed by the same surgical team
using a laparoscopic approach. The OLGB is a simplified
procedure that consists of a unique gastrojejunal anastomosis
between a 30- and 40-mL-sleeve gastric pouch and a jejunal
omega-loop of approximately 200 cm [28].
Liver Biopsy and Histopathological Evaluation
Intraoperatively, fine-needle trucut biopsies were performed
during the laparoscopic OLGB. All tissues were fixed in
10 % buffered formalin and embedded in paraffin. The three
histochemically stained biopsies (hematoxylin and eosin,
Chromotrop Anilinblue and Prussian blue iron stains) were
analyzed and interpreted by two independent, experienced
board-certified pathologists of the General Hospital Vienna,
Austria. The histological scoring system NAFLD activity
score (NAS; from 0 to 8) by Kleiner et al. [29] was used to
evaluate the grade of steatosis (0–3), hepatocyte ballooning
(0–2), lobular inflammation (0–3), and stage of fibrosis with a
4-point scale.
Safety and Adverse Effects
The participants were interviewed after 2 weeks, 1, 2, 3, 4, 5,
and 6 month(s) postoperatively for any signs or symptoms of
vitamin D toxicity or other adverse events, including serious
illness or hospitalizations.
Statistical Analysis
The results are expressed as mean (standard deviation) for
continuous and as percentages for categorical variables. In
order to test for normal distribution, a visual test (histograms
and box plots) was used and the Kolmogorov-Smirnov test
was applied in addition. Statistical significance tests such as t
test or Mann-Whitney U test, and Chi2 test were applied to
assess differences between the intervention and control groups
at baseline. The primary outcome variable 25(OH)D was an-
alyzed according to the intention-to-treat (ITT) principle (in-
cluding all randomized participants). To handle missing data,
the multiple imputation (MI) method was used for the main
analysis [30]. All secondary outcome variables were assessed
by per-protocol analysis (PP; all persons included in the study
without major protocol deviation). The associations of
25(OH)D and PTHi were assessed by multiple and single
linear regression models with backward selection of variables
at a p value threshold of 0.20 or variables entered in the model.
We used repeated measure analysis of covariance (ANCOVA)
using random error (linear mixedmodel) to assess the effect of
time and the interaction for changes in parameters between the
groups, by using different covariance structure models as ap-
propriate and were adjusted for age, sex, and baseline values
to supply an unbiased estimate of the mean group difference
[31].Moreover, a post hoc analysis with Bonferroni correction
was used. Cohen’s d was used to quantify the effect of the
treatment (effect size) based on the mean pre-postchange in
the intervention group minus the mean pre-postchange in the
control group, divided by the pooled pretest standard devia-
tion [32, 33]. Estimates of the prevalence of SHPT and vita-
min D sufficiency between the intervention and control
groups over time were calculated using generalized estimating
equation (GEE) with a logit link function for binary outcomes
and unstructured covariance matrices. With this approach, we
examined effects with time as repeated factor and group as
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between subject factor with prevalence of SHPT and vitamin
D sufficiency (yes, no) as dependent variable, adjusted for
age, sex, and baseline value. All statistical analyses were per-
formed with IBM® SPSS® Statistics for Windows, v23 soft-
ware (IBM Corporation, Armonk, New York, USA). p values
<0.05 were considered statistically significant, and all tests
were two sided.
Results
Study Recruitment and Follow-up
Out of 67 eligible patients, 17 declined to participate (25 %)
(Fig. 1). The remaining 50 patients were randomized and 25
each were allocated either to intervention or control group. In
total, the dropout rate was 6 % (n = 3), 8 % (n = 2) in the
intervention and 4 % (n = 1) in the control group. The final
number of patients in the per-protocol analysis for secondary
outcome measures was 21 in the intervention and 22 in the
control group (Fig. 1). Enrollment took place continuously
from April 2014 to April 2015, however, the number of pa-
tients randomly assigned to each group did not differ by sea-
son (p = 0.972).
Regarding the first, second, and third loading doses in the
first month postoperatively, 100, 100, and 96 % of the
participants took their assigned study drug (cholecalciferol)
or placebo. Adherence to the subsequent maintenance dose
was at 2, 3, 4, 5, and 6 months after surgery at 67, 70, 71,
63, and 61 % without statistically significant differences be-
tween the study groups.
Baseline Characteristics
The baseline characteristics of randomized patients separately
for the respective study groups are shown in Table 1 and in the
supplementary material (Table S1; dietary intake). All patients
had 25(OH)D concentrations below 75 nmol/L. At baseline,
no statistically significant differences between intervention
and control groups were observed, except for serum concen-
tration of PTHi (p = 0.039). Serum 25(OH)D concentration
correlated significantly with season (summer; β = 0.503,
p < 0.001) and age (β = 0.386, p = 0.005).
Change in Primary Outcome Variable
The significant change in serum 25(OH)D during the study is
shown in Fig. 2. Vitamin D supplementation showed a signif-
icant increase in 25(OH)D over time (p < 0.001) and with a
significantly higher 25(OH)D concentration in the interven-
tion compared with the control group (p = 0.046). The differ-
ence between the groups was significantly different at
Fig. 1 CONSORT flow chart of
participant recruitment in the
randomized controlled trial
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2 months (p = 0.031) and 6 months (p = 0.049) postoperative-
ly. Moreover, the intervention group achieved a maximum
25(OH)D concentration of 75.7 nmol/L (standard deviation,
20.5; Cmax) at 4.7 months (1.6; Tmax) with an area under the
curve (AUC) of 339.6 (standard deviation, 103.2) and 52 %
showed a Cmax within the normal range of >75 nmol/L over
the time period. In comparison, the control group demonstrat-
ed a Cmax of 67.5 nmol/L (20.6) at 4.2 months (1.3) with an
AUC of 261.6 (81.7) and 41 % showed a normal Cmax over
the study duration. The AUC differed significantly between
intervention and control groups (p = 0.009). In addition, the
effect size Cohen’s d was 0.87 and can be considered a large
effect size, according to Cohen [32].
By using generalized estimating equation, adjusted for age,
sex, season, and baseline value, we found no significant dif-
ference in the estimates of the prevalence of vitamin D suffi-
ciency (25(OH)D ≥75 nmol/L) between the intervention and
control groups (p = 0.274), but an increase in the prevalence
over time (p = 0.008): intervention vs. control: no difference at
baseline; after 2 weeks, 2 vs. 1 %; 1 month, 5 vs. 3 %;
2 months, 6 vs. 3 %; 3 months, 24 vs. 15 %; 4 months, 23
vs. 13 %; 5 months, 40 vs. 34 %; and after 6 months, 34 vs.
22 %. Moreover, patients in the intervention group showed an
adjusted odds ratio of 1.9 (95 % CI = 0.6, 5.9; p = 0.274) for
vitamin D repletion compared with the control group.
Change in Secondary Variables
Changes in BMI, waist circumference, intake of supplements
(vitamin D and calcium), and serum parameters of vitamin D
metabolism are shown in Table 2. Vitamin D intake via sup-
plementation significantly changed over time from baseline
(p < 0.001) between the groups (p < 0.001) with differences
at 0.5, 1, and 2 months and showed a group and time interac-
tion (p < 0.001), as the change over time differed between the
groups. The activated serum vitamin D concentration,
1,25(OH)2D3, changed significantly over time (p = 0.012)
and after 3 months differed between the groups (p = 0.050).
Ca supplementation, serum PTHi, Ca, and corrected calcium
concentrations showed no significant changes over time,
Table 1 Patients’ characteristics
at baseline between intervention
and control groups
Total (n = 50) Intervention (n = 25) Control (n = 25)
Age (years) 42.4 (12.7) 43.0 (12.6) 41.8 (13.0)
BMI (kg/m2) 43.8 (4.3) 44.6 (4.2) 42.9 (4.3)
Waist circumference (cm) 127.4 (10.6) 128.3 (9.7) 126.5 (11.5)
Number of drugs 5.8 (8.1) 5.8 (8.3) 5.8 (8.0)
Female (n (%)) 40 (80) 20 (80) 20 (80)
Comorbidities
Cardiovascular (n (%)) 28 (56) 13 (52) 15 (60)
Diabetes mellitus (n (%) 13 (26) 9 (36) 4 (18)
Depression (n (%)) 8 (16) 2 (8) 6 (24)
Significant liver fibrosis (n (%))a 14 (30) 9 (43) 5 (20)
Supplements intake
Vitamin D (IU/day)b 252.3 (675.2) 130.3 (407.3) 374.4 (856.7)
Calcium (mg/day)c 360.0 (339.4) 600.0 (0.0) 120.0 (0.0)
Time outside (h/week) 13.7 (11.1) 13.7 (10.0) 13.8 (12.3)
Serum parameters
25(OH)D (nmol/L) 39.0 (14.4) 38.8 (14.2) 39.3 (14.8)
1,25(OH)2D (pg/mL) 46.9 (16.2) 44.9 (14.2) 48.8 (17.9)
PTHi (pg/mL) 48.7 (14.3) 45.1 (14.7) 52.3 (13.3)*
Calcium (mmol/L) 2.3 (0.1) 2.3 (0.2) 2.3 (0.1)
Corr. Ca (mmol/L) 2.2 (0.1) 2.2 (0.1) 2.2 (0.1)
Note: Data are presented as mean (standard deviation) or percentages. T test or Mann-Whitney U test depending
on distribution
25(OH)D 25-hydroxy vitamin D, 1,25-(OH)2D 1,25-dihydroxy vitamin D, PTHi parathyroid hormone intact, Ca
calcium, corr. Ca corrected total calcium, BMI body mass index
*p < 0.05 (intervention vs. control)
a Significant liver fibrosis F ≥ 2
bVitamin D via supplements before receiving the study drug of cholecalciferol
c n = 2 received calcium supplementation (n = 1 intervention, n = 1 control)
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between the study groups, and no group and time interactions.
Dietary intake of energy, fat, carbohydrate, protein, calcium,
and vitamin D is shown in Supplementary Material Table S2.
The time spent outdoors (h/week; between 9 a.m. and 3 p.m. a
day) was similar between the groups (intervention vs. control,
0.7 h/week (95 % CI = −3.3, 4.7), p = 0.717), over the time
(−1.5 h/week (95%CI = −6.6, 3.6), p = 0.345) and showed no
group and time interactions (p = 0.877).
Impact of Vitamin D Supplementation in Patients
with Liver Fibrosis
Figure 3 shows 25(OH)D concentrations in patients without
(F ≤ 1; n = 29; Fig. 3a) and with (F ≥ 2; n = 14; Fig. 3B)
significant liver fibrosis. Patients with fibrosis showed a sig-
nificant group and time interactions (p = 0.050) with signifi-
cant differences at 5 months (p = 0.050) and 6 months
(p = 0.022) after surgery, as the concentration in the interven-
tion group (n = 9) increased, while it decreased in the control
group (n = 5). In comparison, 25(OH)D concentrations in
patients without fibrosis significantly increased over the time
(p < 0.001), but the increase was similar between the groups
(intervention: n = 12, control: n = 20; p = 0.297).
Parathyroid Hormone Suppression
We observed a significant suppression of PTHi in the inter-
vention but not in the control group. The prevalence of SHPT
decreased over the time (p = 0.039) and differed significantly
between the groups (p = 0.038) with differences at 2 weeks
(p = 0.024), 2 months (p = 0.046), 3 months (p = 0.032),
4 months (p = 0.042), and at the end of the study (6 months;
p = 0.045; Fig. 4). Moreover, patients in the intervention
group had an odds ratio of 0.3 (95 % CI = 0.1, 0.9;
p = 0.038) for SHPT compared with the control group. PTHi
was associated with 25(OH)D concentrations (β = −0.393,
p < 0.001) and BMI (β = 0.164, p = 0.035) over the time
course, adjusted by age and sex.
Safety
No serious adverse events related to vitamin D3 supplementa-
tion were observed between the groups. No individual in ei-
ther group had evidence of hypercalcemia (>10.5 mg/dL) dur-
ing the study period (before and 6 months after surgery).
There were two serious adverse events over the whole
study period: serious illnesses (myocardial infarction) before
the bariatric procedure with consequent cancelation of the
scheduled operation and after surgery (liver hematoma) as a
consequence of liver biopsy during surgery. Therefore, no
serious adverse event could be related to the study medication
of cholecalciferol as both occurred before administration.
Discussion
The aim of this study was to examine the efficacy and safety of
a forced vitamin D dosing regimen vs. conventional supple-
mentation on parameters of vitamin D metabolism in bariatric
patients undergoing OLGB during 6 months. We have shown
recently that 80 % of patients remained vitamin D deficient
following OLGB, despite taking individually adjusted vitamin
D3 supplementation of 200–3000 IU/day [18]. Thus, the cur-
rent study adds new evidence regarding postoperative preven-
tion and treatment of vitamin D deficiency in bariatric pa-
tients. This is particularly important for patients undergoing
OLGB, which is a rather new bariatric procedure with higher
weight loss compared with the Roux-en-Y gastric bypass [34].
Our current trial led to four main outcomes: First, due to
the loading doses in the first month postoperatively and sub-
sequent supplementation with maintenance doses, we ob-
served a significantly higher increase in 25(OH)D concentra-
tion and AUC during the study period in the intervention
group compared with the control group. Second, the interven-
tion group had a significantly lower prevalence and odds rate
of SHPTcompared with the control group. PTHi was inverse-
ly associated with 25(OH)D concentrations over the time
course. This could imply that higher vitamin D concentrations
are needed to prevent SHPT which is associated with preop-
erative obesity and postoperative malabsorption [35]. Third,
this vitamin D supplementation regimen is safe as we ob-
served no (serious) adverse events related to the study medi-
cation. Serum calcium concentration remained stable
Fig. 2 Change in serum 25-hydroxy vitamin D concentration (nmol/L)
over the time between intervention and control groups. Note: 25(OH)D
25-hydroxy vitamin D. Repeated measure analysis of variance and post
hoc analysis with Bonferroni correction, adjusted for baseline value,
season, age, and sex with intention-to-treat analysis: intervention






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































throughout the study in each group despite the increasing di-
etary calcium intake. Fourth, the loading dose regimen was
effective in increasing 25(OH)D concentrations in patients
with significant liver fibrosis while this was not the case for
the conventional dosing regimen.
To our knowledge, only one randomized controlled trial
with higher doses of vitamin D in bariatric patients was pub-
lished [35]. The authors randomized patients after Roux-en-Y
gastric bypass to three doses of cholecalciferol (800, 2000,
and 5000 IU/day). After 12 months, 44, 78, and 70 % of the
patients reached sufficient vitamin D concentrations [35]. All
other studies have either a retrospective cross-sectional de-
sign, are pilot studies, or have prospective but non-
randomized study design [36–38]. Thus, the results of our
study represent the best available evidence for an effective
vitamin D substitution following gastric bypass. However,
even in the intervention group, there was a high prevalence
of low 25(OH)D concentration (<75 nmol/L) 6 months after
surgery (66 % in the intervention group vs. 78 % in the con-
trols). As the majority of the patients (96 %) required all three
loading doses, it can be suggested that patients with vitamin D
deficiency and planned OLGB should receive the vitamin D3
loading dose already before surgery. Nevertheless, this regi-
men needs to be evaluated in future prospective studies.
Moreover, considering the use of the supplement matrix, a
systematic review showed a higher vitamin D bioavailability
by using an oil-soluble vehicle which led to a larger increase
in serum 25(OH)D levels compared with non-oily vehicles in
healthy individuals [39]. A recent randomized controlled trials
also confirmed this finding [40]. Furthermore, while the used
type of vitamin D3 supplementation in our study has not been
examined in bariatric patients until now, it was assessed in a
similar manner in obese children, in nursing home patients,
patients with hip fracture surgery, and with inflammatory/
autoimmune rheumatic diseases [41–44]. These studies have
also shown superior effects of vitamin D3 loading dose sup-
plementation similar to our study.
In the current study, the loading dose regimen with vitamin
D3 was the only one effective in increasing 25(OH)D concen-
trations in patients with significant liver fibrosis over the 6-
month study period in contrast to the conventional regimen
using the same maintenance dose. This is an unexpected and
remarkable finding. It is well established that serum 25(OH)D
Fig. 3 Change in serum 25-hydroxy vitamin D concentration (nmol/L)
over the time between intervention and control groups in patients without
(a) and with significant fibrosis (b). Note: 25(OH)D 25-hydroxy vitamin
D. Repeated measure analysis of variance and post hoc analysis with
Bonferroni correction, adjusted for baseline value, vitamin D dose,
season, age, and sex and intention-to-treat analysis: intervention
(n = 25) and control (n = 25). Significant fibrosis = F ≥ 2, n = 14. No
significant fibrosis = F ≤ 1, n = 29. Error bars: standard deviation;
*p < 0.05 (intervention vs. control)
Fig. 4 Estimates of the prevalence of secondary hyperparathyroidism
over the time between intervention and control groups. Note: SHPT
secondary hyperparathyroidism. Generalized estimating equations
(GEE) with a logit link function for binary outcomes, adjusted for
baseline value and sex; bars represent standard error; at 6 months,
n = 21 in intervention and n = 22 in control group; *p < 0.05
(intervention vs. control)
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concentrations are significantly reduced in various types of
chronic liver disease [8, 9, 45]. Several responsible mecha-
nisms have been identified, whose relative contributions seem
to vary depending on the etiology and the stage of the liver
disease. Reduced vitamin D absorption in the terminal ileum
due to decreased availability of bile acids has been implicated
[46]. Significantly reduced expression of the hepatic vitamin
D 25-hydroxylases CYP2R1 and CYP27A1 was described in
chronic hepatitis C. In the same immunohistochemic study,
reduced expression of these enzymes was also found in
NASH; however, it did not reach statistical significance in this
condition [47]. Serum concentrations of vitamin D-binding
protein (VDBP) were found to be significantly decreased in
NAFLD and to display a significant inverse correlation with
the stage of fibrosis [48]. As VDBP is the main vitamin D
carrier in blood, a decrease in its concentration would appear a
likely contributor to lower total 25(OH)D concentration.
Finally, genetic studies revealed an association of genetic var-
iants in the vitamin D system with liver stiffness, suggesting a
causal role in the pathogenesis of liver fibrosis [49]. This is
also supported at the mechanistic level by evidence that vita-
min D has metabolic, anti-inflammatory and anti-fibrotic ef-
fects on hepatocytes and non-parenchymal hepatic cells in
NAFLD [50]. In that regard, vitamin D has been proposed
as a potential therapeutic option for liver fibrosis [10].
Nevertheless, very few studies have been performed to eval-
uate the effects of vitamin D supplementation on liver fibrosis
[51]. The significantly divergent time courses of 25(OH)D
concentrations between loading dose and control group
among patients with liver fibrosis over a period of 6 months
in our present study is hard to explain by pharmacokinetic
considerations alone. Therefore, although n = 14 is, of course,
not sufficient to draw any reliable conclusions, it is tempting
to attribute them to some pharmacologic effects of the initial
megadoses of up to 3 × 100,000 units vitamin D3 in the inter-
vention group, likely involving the described mechanisms
[10] and presumably able to overcome some of the distur-
bances of the hepatic vitamin D metabolism associated with
liver fibrosis. If confirmed, this finding would impact the de-
sign of future studies addressing the therapeutic utility of vi-
tamin D in liver fibrosis.
Our study has some limitations: First, the sample size is
rather small, although, it was based on the sample size calcu-
lation taking into account differences of serum 25(OH)D con-
centrations at 6 months between intervention and control
groups. As we were able to find significant differences be-
tween the study groups regarding the primary outcome vari-
able, the sample size can be regarded as sufficient. Second,
our study included a high percentage of women (80 %); how-
ever, this is very common in bariatric patients. Third,
underreporting of food-intake has been frequently observed
in bariatric patients [52]. To minimize this phenomenon, our
patients received dietary counseling by a registered dietician
before surgery to keep a low-energy and low-carbohydrate
diet and the dietary records were documented 1 week before
surgery. All these facts might have contributed to the reduced
preoperative energy intake.
Besides the significant and relevant findings, the double-
blind, randomized, placebo-controlled study design and the
close monitoring during the first 6 months postoperatively
are further strengths of our study. Moreover, liver fibrosis
has been biopsy proven as the current gold standard for the
assessment of liver disease. This study provides detailed pre-
and postoperative data of patients undergoing OLGB as a
rather new bariatric procedure.
In conclusion, our findings indicate that starting the vita-
min D3 supplementation with a high loading dose in the first
month postoperatively followed bymaintenance dose is effec-
tive and safe in achieving higher vitamin D concentrations in
vitamin D-deficient bariatric patients receiving OLGB.
Additionally, this dosing regimen appears to be the only one
effective in patients with significant liver fibrosis. This is a
remarkable finding of potentially high clinical relevance and
requires further investigation. Larger studies regarding vita-
min D supplementation in patients with liver fibrosis and a
potential beneficial effect on this condition are warranted as
both, morbid obesity and vitamin D deficiency are related to
NAFLD.
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